Risk factors of thyroid eye disease

MH Lee, YH Chin, CH Ng, KRY Nistala, ZGW Ow… - Endocrine Practice, 2021 - Elsevier
Objective To examine risk factors that might be associated with thyroid eye disease (TED) in
patients with Graves' disease (GD), which may guide physicians in the prevention and …

Thyroid eye disease: From pathogenesis to targeted therapies

JS Yoon, DO Kikkawa - Taiwan Journal of Ophthalmology, 2022 - journals.lww.com
Thyroid eye disease (TED) is the most common extrathyroidal manifestation of autoimmune
Graves' hyperthyroidism. TED is a debilitating and potentially blinding disease with unclear …

A systematic review of multimodal clinical biomarkers in the management of thyroid eye disease

SHL Poon, JJC Cheung, KC Shih, YK Chan - Reviews in Endocrine and …, 2022 - Springer
Abstract Thyroid Eye Disease (TED) is an autoimmune disease that affects the extraocular
muscles and periorbital fat. It most commonly occurs with Graves' Disease (GD) as an …

[HTML][HTML] Molecular biomarkers in thyroid eye disease: a literature review

HO Ueland, MT Neset, P Methlie… - Ophthalmic Plastic & …, 2023 - journals.lww.com
Purpose: Thyroid eye disease (TED) is the most common extrathyroidal manifestation of
Graves disease. Patients may be severely affected with eyelid retraction, exophthalmos …

Association of serum Cyr61 levels with peripheral arterial disease in subjects with type 2 diabetes

B Feng, G Xu, K Sun, K Duan, B Shi… - Cardiovascular …, 2020 - Springer
Background The prevalence of peripheral artery disease (PAD) is obviously increased in
patients with diabetes. Existing evidence shows that cysteine-rich angiogenic inducer 61 …

Simvastatin inhibits CYR61 expression in orbital fibroblasts in Graves' ophthalmopathy through the regulation of FoxO3a signaling

YH Wei, SL Liao, CC Wang, SH Wang… - Mediators of …, 2021 - Wiley Online Library
Graves' ophthalmopathy (GO), which is characterized by orbital tissue inflammation,
expansion, and fibrosis, is the ocular manifestation in 25% to 50% of patients with Graves' …

Cross-sectional and longitudinal associations of serum Cysteine-rich 61 with severity and prognosis among community-acquired pneumonia patients in China

MX Yao, JY Cheng, Y Liu, J Sun, DX Hua, QY He… - Frontiers in …, 2022 - frontiersin.org
Background Cysteine-rich 61 (CYR61) is implicated in many pulmonary diseases. However,
the relationship between CYR61 and community-acquired pneumonia (CAP) patients was …

Cyr61 Alleviates Cholangitis by Inhibiting Cytotoxic Effects of CD8+ T Cells on Biliary Epithelial Cells

T Cheng, H Li, X Luo, L Ju, L Chen, J Shao… - Current Medical …, 2021 - Springer
Objective Primary biliary cholangitis (PBC) is a chronic progressive cholestatic liver disease.
In recent years, researchers have found that cysteine-rich angiogenic inducer 61 (Cyr61 …

Serum CYR61 Levels are Associated with Graves' Ophthalmopathy and Smoking in Patients with Graves' Disease

P Cerri, B Shahida, M Lantz… - Hormone and Metabolic …, 2022 - thieme-connect.com
Smoking is a well-known risk factor for Graves' ophthalmopathy (GO) in patients suffering
from Graves' disease (GD). Cysteine-rich angiogenic inducer 61 (CYR61), which has …

[PDF][PDF] Molecular Mechanisms of Graves' Ophthalmopathy. A focus on smoking and radioiodine.

B Shahida - 2021 - portal.research.lu.se
308966 - Bushra Shahida Page 1 Molecular Mechanisms of Graves' Ophthalmopathy. A focus
on smoking and radioiodine. Shahida, Bushra 2021 Document Version: Publisher's PDF, also …